A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatment of Human Immunodeficiency Virus.

Acquired Immunodeficiency Syndrome (AIDS) is a sexually transmitted disease that can be passed from partner to partner, mother to child, or through blood exchange using infected syringes. AIDS symptoms might vary depending on characteristics such as age, gender, and physical activity. Headaches, muscle and joint discomfort, rashes, diarrhoea, weight loss, coughing, night sweats, sore throat, stomatitis, swollen lymph nodes, malaise, oral yeast infections, shingles (herpes zoster), and lung infections are all common symptoms. The Food and medication Administration (FDA) of the United States authorised Lenacapavir, a novel AIDS therapy medication, in 2022. Lenacapavir is a capsid inhibitor available in tablet and injection form that directly targets the Human Immunodeficiency Virus Type 1 (HIV-1) Capsid Protein. Various research and papers, like the Capella study, which assessed the safety and efficacy of subcutaneous Lenacapavir, were used to assess the safety and efficacy of Lenacapavir. The Calibrate study shed light on the absence of phenotypic resistance to Lenacapavir in HIV Gag cleavage site mutants and isolates resistant to existing medication classes. These studies also included data from a proof-of-concept clinical research on HIV patients examining phenotypic resistance to Lenacapavir and its efficacy as a monotherapy. The approval of Lenacapavir represents a viable new therapy option for those living with HIV. Its method of action, as well as promising safety and efficacy results from numerous studies, offer hope for better outcomes in the treatment of this severe disease. [ABSTRACT FROM AUTHOR]